Journal article
The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review
Abstract
BACKGROUND AND OBJECTIVE: Since approval of sorafenib in 2008, systemic therapy has been established as the main treatment option for advanced hepatocellular carcinoma (HCC). Recently, immune checkpoints inhibitors (ICIs) have been extensively tested in this setting. Multiple ICI combination regimens have recently received regulatory approval and new data continues to emerge. The purpose of this review is to provide a comprehensive summary of …
Authors
Meyers BM; Knox JJ; Liu DM; McLeod D; Ramjeesingh R; Tam VC; Lim HJ
Journal
Cancer Treatment Reviews, Vol. 118, ,
Publisher
Elsevier
Publication Date
7 2023
DOI
10.1016/j.ctrv.2023.102584
ISSN
0305-7372